At a glance
ClinicalIndex Comparison RecordN/ACompleted· 53 enrolled
Drug / intervention
Azithromycin +1 moredrug
Likely dose
Azithromycin 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Macrolide Treatment on a Novel Pathway of Neutrophilic Inflammation in COPD
In Brief
An observational study evaluating Azithromycin and Placebo for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 53 participants across 1 site.
Detailed Summary
Chronic obstructive pulmonary disease (COPD) is a chronic lung disease. Azithromycin, an antibiotic, may be beneficial at reducing the symptoms and severity of the disease. This study will analyze previously collected study data to evaluate the anti-inflammatory properties of azithromycin and determine how azithromycin affects the frequency and severity of COPD exacerbations.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedOct 2007
Primary CompletionJul 2011
Study CompletionJul 2012
TodayJul 2026
First PostedOct 25, 2007
Enrollment StartAug 1, 2007
Primary CompletionJul 1, 2011
Study CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 18.7 years ago
Interventions
Azithromycindrug
250 mg daily
Placebodrug
Daily